HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

Prof. Dr. HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

prof.Dr. Hossam M. Hassan , College of Pharmacy, University of Kut,Iraq

Dr. Hossam Mokhtar Hassan 🇪🇬 is an esteemed Associate Professor of Pharmacognosy at Nahda University and Beni-Suef University, Egypt 🧪. With a Ph.D. in Pharmaceutical Sciences and postdoctoral training at UCSD’s Scripps Institute 🌊, his expertise lies in natural product chemistry, marine pharmacognosy, and phytotherapy 🌿. He currently serves as Vice-Dean for Postgraduate Affairs and General Manager of the Central Research Lab at NUB 🧫. A dedicated educator and researcher, he has received multiple accolades 🏆 and remains active in scientific societies, pushing the boundaries of drug discovery from natural and marine sources 🔬.

Professional Profile:

Scopus

🎓 Education & Experience 

🎓 Education:

  • 🧪 Ph.D. in Pharmaceutical Sciences, University of Louisiana & Beni-Suef University, 2010

  • 🌿 M.Sc. in Pharmacognosy, Cairo University, 2006

  • 💊 B.Sc. in Pharmaceutical Sciences (Honors), Cairo University, 2000

  • 🌊 Postdoc at Scripps Institute of Oceanography, UCSD, 2013-2014

💼 Experience:

  • 🏛️ Vice-Dean for Postgraduate Affairs, Faculty of Pharmacy, NUB (2019–Present)

  • 👨‍🏫 Associate Professor, Nahda & Beni-Suef Universities (2016–Present)

  • 🧪 General Manager, Central Research Lab, NUB (2017–Present)

📈 Professional Development 

Dr. Hassan has continually honed his skills through international fellowships and academic training 🧳. He has mastered advanced techniques such as NMR, HPLC, LC/MS, GC/MS, and molecular docking for natural product analysis 🔬🧫. His scientific capabilities span pharmacophore modeling, phytochemistry, and marine bioprospecting 🌊🌱. He has also developed leadership skills as a strategic planning team leader at NUB 🗂️, with training in effective teaching, decision-making, communication, and problem-solving 🎯🗣️. His active memberships in the American Society of Pharmacognosy and the Egyptian Syndicate of Pharmacists reflect his commitment to global scientific communities 🌍📚.

🔍 Research Focus Category 

Dr. Hassan’s research is centered on natural product drug discovery, especially from marine and plant-derived sources 🌊🌿. He isolates bioactive compounds from symbiotic bacteria, fungi, and medicinal plants to explore their pharmacological potential 💊. His work involves biotransformation, chemical derivatization, and 3D-QSAR studies for structure–activity relationships 🧪🧬. His expertise in phytochemistry and marine pharmacognosy contributes to identifying novel therapeutic agents against microbial infections, cancer, and fertility disorders 🔬👨‍⚕️. Integrating cutting-edge analytical and modeling techniques, he aims to harness nature’s biodiversity for modern medicine 🌍🧫.

🏆 Awards & Honors 

  • 🏅 Best Master’s Thesis, Faculty of Pharmacy, Cairo University, 2006

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2007

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2012

  • 🎓 Best Ph.D. Thesis in Pharmacognosy, All Egyptian Pharmacy Faculties, 2012

Publication Top Notes:

1. Pachycladins A–E: Eunicellin-Based Diterpenoids

Hassan HM, Khanfar MA, Elnagar AY, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Pachycladins A–E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the Red Sea soft coral Cladiella pachyclados. J Nat Prod. 2010; 73(5):848–853.
https://doi.org/10.1021/np900858m

🔬 Summary:
This study reports the isolation of five new Eunicellin-based diterpenoids, named Pachycladins A–E, from the Red Sea soft coral Cladiella pachyclados. These compounds were shown to inhibit the migration and invasion of prostate cancer cells, indicating promising anticancer potential through marine natural product chemistry.

2. 3D-QSAR of Semisynthetic Eunicellin Diterpenoids

Hassan HM, Elnagar AY, Khanfar MA, Sallam A, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Design and 3D-quantitative structure-activity relationship of semisynthetic eunicellin-based diterpenoids as prostate cancer migration and invasion inhibitors. Eur J Med Chem. 2011; 46(4):1122–1130.
https://doi.org/10.1016/j.ejmech.2011.01.055

🧪 Summary:
The paper explores the design and synthesis of semisynthetic derivatives of eunicellin-based diterpenoids and develops a 3D-QSAR model to evaluate their anticancer activity. These analogs demonstrated enhanced inhibition of prostate cancer cell migration and invasion, highlighting their potential for further drug development.

3. Semisynthetic Sarcophine Derivatives as Anticancer Agents

Hassan HM, Sallam AA, Mohammed R, Hifnawy MS, Youssef DT, El Sayed KA. Semisynthetic analogues of the marine cembranoid sarcophine as prostate and breast cancer migration inhibitors. Bioorg Med Chem. 2011; 19(16):4928–4934.
https://doi.org/10.1016/j.bmc.2011.06.073

🧬 Summary:
This study details the synthesis of analogues of sarcophine, a marine cembranoid, and evaluates their ability to inhibit migration in prostate and breast cancer cell lines. Several derivatives showed strong bioactivity, offering new leads in anticancer drug discovery.

4. Decorosides A and B: Cytotoxic Flavonoid Glycosides

Mostafa ER, Hossam MH, El-Shaimaa AA, Marcel J, Rainer E. Decorosides A and B, cytotoxic flavonoid glycosides from the leaves of Rhododendron decorum. Nat Prod Commun. 2014; 9(4):473–476.
https://doi.org/10.1177/1934578X1400900408

🌿 Summary:
The article reports the isolation of two new flavonoid glycosides—Decorosides A and B—from Rhododendron decorum. Both compounds exhibited cytotoxic effects, contributing to the growing interest in plant-derived anticancer agents.

5. Salinamide F: A Marine-Derived Depsipeptide Antibiotic

Hossam MH, David D, Kyoung HJ, Richard HE, William F. Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp. J Antibiot. 2015; 68(3):206–210.
https://doi.org/10.1038/ja.2014.127

🧫 Summary:
This paper describes the discovery of Salinamide F, a novel depsipeptide isolated from Streptomyces sp.. The compound functions as a potent inhibitor of bacterial RNA polymerase, demonstrating promise as a new class of antibiotic against resistant bacteria.

6. Bioactivity of Pulicaria undulata Metabolites

Taha AH, Sayed AE-T, Hossam MH, Mona HH. Cytotoxic and antioxidant activities of secondary metabolites from Pulicaria undulata. Int J Pharm Pharm Sci. 2016; 8(9):150–155.
https://innovareacademics.in/journals/index.php/ijpps/article/view/13208

🌼 Summary:
The study investigates secondary metabolites from Pulicaria undulata, demonstrating both cytotoxic and antioxidant activities. It highlights the plant’s potential as a natural source of therapeutic agents targeting oxidative stress and cancer.

Conclusion:

Prof. Dr. Hossam M. Hassan exemplifies the qualities of a Best Researcher Award recipient through:

  • Innovative scientific contributions in natural products and pharmaceutical chemistry,

  • Strategic academic leadership and international collaboration,

  • Sustained impact on public health-oriented drug discovery.

His work not only advances science but also addresses critical global health challenges such as cancer, antibiotic resistance, and oxidative stress disorders.

Dr. Rahmuddin khan | Pharmaceutics Awards | Best Researcher Award

Dr. Rahmuddin khan | Pharmaceutics Awards | Best Researcher Award

Dr. Rahmuddin khan, jamia hamdard, India

Dr. Rahmuddin is a skilled pharmaceutics researcher specializing in nano-based drug delivery systems for topical diseases, with a primary focus on psoriasis. Currently affiliated with the Nanomedicine Lab at Jamia Hamdard, New Delhi, he has a rich background in developing functional excipients and enhancing drug solubility through novel formulations. His academic path, from a Bachelor’s to a Ph.D. in Pharmaceutics at Jamia Hamdard, has cultivated his expertise across several scientific domains. Rahmuddin’s research includes hands-on experience with regulatory safety, non-clinical assessments, and industry-sponsored projects involving fulvic acid-based nanoformulations. Known for his analytical thinking, scientific writing, and mentorship, he has published extensively in reputable journals, showcasing advancements in nanoemulsion gels for conditions like psoriasis and tuberculosis. His collaborative work with New Zealand Fulvic Acid Limited and Reckitt Benckiser demonstrates his commitment to bridging industry with academic research for innovative therapeutic solutions.

Professional Profile:

Google Scholar

Suitability for the Best Researcher Award:

Dr. Rahmuddin is a highly deserving candidate for the Best Researcher Award due to his significant contributions to the field of pharmaceutics, particularly in the area of nano-based drug delivery systems for topical diseases such as psoriasis. His innovative research focuses on enhancing drug solubility and improving the effectiveness of topical treatments through novel formulations, including nanoemulsion gels. Dr. Rahmuddin’s academic background, culminating in his Ph.D. from Jamia Hamdard, showcases his deep understanding of pharmaceutics and his dedication to advancing drug delivery systems. His work with industry collaborators like New Zealand Fulvic Acid Limited and Reckitt Benckiser demonstrates his ability to bridge the gap between academia and industry, driving practical solutions for complex medical challenges.

🎓Education :

Rahmuddin completed his entire academic journey in Pharmaceutics at Jamia Hamdard, New Delhi, earning his Ph.D. in 2023. His doctoral thesis, titled “Novel Functional Excipient Appended System for Psoriasis,” explored advanced nano-based drug delivery systems, aimed at enhancing topical treatments. Prior to his Ph.D., he completed his M.Pharm in 2018, where he focused on “Exploration of Novel Peat-Sourced Fulvic Acid for Solubility Improvement of BCS Class II Drugs.” This research tackled the challenge of drug solubility by investigating natural compounds with pharmaceutical potential. He began his academic career with a B.Pharm in 2016 from the same institution, laying a solid foundation in pharmacy, pharmaceutics, and research methodologies. Throughout his academic journey, he developed strong technical expertise in drug formulation, excipient selection, and nano-delivery systems, equipping him with the necessary skills to innovate within the field of targeted drug delivery.

🏢Experience :

Rahmuddin’s professional experience spans academia, industry collaboration, and regulatory roles. His most recent role as a Consumer Safety Assistant at Reckitt Benckiser (May–Oct 2024) involved ensuring regulatory compliance and conducting non-clinical safety assessments. During his M.Pharm, he worked as a Research Associate on an industry-sponsored project with New Zealand Fulvic Acid Limited, focused on fulvic acid-based nanoformulations, an experience that honed his skills in drug delivery for pharmaceutical applications. His extensive research as a Ph.D. candidate at Jamia Hamdard (Dec 2018–Nov 2023) allowed him to specialize in topical drug delivery systems and provided opportunities to mentor M.Pharm and Ph.D. students. He has gained substantial laboratory experience, working with equipment like UV spectrophotometers, HPLC, tablet compression machines, and dissolution apparatuses, making him proficient in both theoretical knowledge and practical skills essential for pharmaceutical research.

🏅Awards and Honors :

Rahmuddin has received recognition for his work through various academic and industry-sponsored projects. Notably, his collaboration with New Zealand Fulvic Acid Limited on a project involving fulvic acid-based nanoformulations earned him significant acclaim, highlighting his contributions to innovative drug delivery research. His dedication to advancing drug solubility and effectiveness has been acknowledged within the academic community, where he has been a mentor and guide for students exploring solutions for complex diseases like psoriasis and tuberculosis. His publications in reputable journals, featuring targeted treatments and polysaccharide-based nano-drug delivery vehicles, showcase his commitment to expanding the applications of nano-based therapies. Through his professional experience and academic guidance, Rahmuddin continues to impact the field of pharmaceutics, bridging industry needs with academic insights to support advancements in the treatment of chronic diseases.

🔬Research Focus :

Rahmuddin’s research centers on the development of nano-based drug delivery systems for topical treatments, especially focusing on diseases like psoriasis. His work includes the creation of innovative excipients and nanoemulsion gels that improve drug solubility and targeted delivery, addressing issues faced with conventional formulations. In collaboration with New Zealand Fulvic Acid Limited, he has explored the pharmaceutical potential of fulvic acid for enhancing drug solubility, contributing to advancements in drug delivery systems. His technical skills encompass various analytical tools, including HPLC, UV spectrophotometry, and tablet compression machines, allowing him to design and assess complex formulations. Rahmuddin’s research portfolio spans a broad range of disease models beyond psoriasis, including acne and tuberculosis, exemplifying his commitment to leveraging nanotechnology for enhanced therapeutic outcomes. His contributions to scientific literature and mentorship to upcoming researchers further solidify his role as an innovative force in pharmaceutics.

Publication Top Notes:

  • “In vitro and in vivo investigation of a dual-targeted nanoemulsion gel for the amelioration of psoriasis”
    • Citations: 24
  • “A pharmaco-technical investigation of thymoquinone and peat-sourced fulvic acid nanoemulgel: a combination therapy”
    • Citations: 16
  • “Pharmacokinetic evaluation of fulvic acid-ketoconazole complexes: A validation and line extension study”
    • Citations: 7
  • “Neuroprotective effects of trigonelline in kainic acid-induced epilepsy: Behavioral, biochemical, and functional insights”
    • Citations: 5
  • “COVID-19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues”
    • Citations: 4